中文名稱:克唑替尼 | 英文名稱:Crizotinib |
CAS:877399-52-5 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.87% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T1661 |
名稱 | Crizotinib |
描述 | Crizotinib (PF-02341066) is a small molecule tyrosine kinase inhibitor that inhibits c-MET and ALK receptors (IC50=8/20 nM), is ATP-competitive, and also inhibits ROS1. Crizotinib exhibits antitumor activity and inhibits tumor growth. |
細(xì)胞實(shí)驗(yàn) | Cells were seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media (with 0.04% BSA) after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors were added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells were washed once with HBSS supplemented with 1 mmol/L Na3VO4, and protein lysates were generated from cells. Subsequently, phosphorylation of selected protein kinases was assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates were (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase-conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethylbenzidine peroxidase substrate to initiate a colorimetric reaction that was stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer [1]. |
激酶實(shí)驗(yàn) | c-Met catalytic activity was quantitated using a continuous-coupled spectrophotometric assay in which the time-dependent production of ADP by c-Met was determined by analysis of the rate of consumption of NADH. NADH consumption was measured by a decrease in absorbance at 340 nm by spectrophotometry at designated time points. To determine Ki values, PF-2341066 was introduced into test wells at various concentrations in the presence of assay reagents and incubated for 10 min at 37°C. The assay was initiated by the addition of the c-Met enzyme [1]. |
動(dòng)物實(shí)驗(yàn) | Daily treatment with PF-2341066 given in water by oral gavage was initiated when tumors were 100 to 600 mm^3 in volume. Tumor volume was determined by measurement with electronic Vernier calipers, and tumor volume was calculated as the product of its length × width2 × 0.4. Tumor volume was expressed on indicated days as the median tumor volume ± SE indicated for groups of mice. Percent (%) inhibition values were measured on the final day of study for drug-treated compared with vehicle-treated mice and are calculated as 100 × {1?[(TreatedFinal day ? TreatedDay 1)/(ControlFinal day ? ControlDay 1)]}. Tumor regression values were determined by calculating the ratio of median tumor volumes at the time when treatment was initiated to the median tumor volume on the final day of study for a given treatment group. Significant differences between the treated versus the control groups (P ≤ 0.001) were determined using one-way ANOVA [1]. |
體外活性 | 方法:HMVEC 內(nèi)皮細(xì)胞用 Crizotinib (0.083-1.33 μmol/L) 處理 7 天,使用顯微鏡觀察形態(tài)。 結(jié)果:Crizotinib 在纖維蛋白凝膠中抑制血清刺激的 HMVEC 分支小管形成。[1] 方法:9 種肺癌癥細(xì)胞用 Crizotinib 處理 72 h,使用 Cell Titer-Glo Luminescent Cell Viability Assay 檢測(cè)細(xì)胞活力。 結(jié)果:具有 MET 擴(kuò)增的兩種細(xì)胞系,EBC-1 和 H1993 均對(duì) Crizotinib 敏感,IC50 值≤10 nM。相反,Crizotinib 沒(méi)有顯著抑制具有 MET 突變 (H2122、H1437 和 H596)、具有 EGFR 突變 (PC9 和 HCC827) 或沒(méi)有這種基因擴(kuò)增或突變 (A549 和 H1299) 的癌癥細(xì)胞的增殖。[2] |
體內(nèi)活性 | 方法:為檢測(cè)體內(nèi)抗腫瘤活性,將 Crizotinib (3.125-50 mg/kg) 灌胃給藥給攜帶 GTL-16 異種移植物的 nu/nu 小鼠,每天一次,持續(xù)十一天。 結(jié)果:在 50 mg/kg/天的劑量水平下,100% 的腫瘤生長(zhǎng)抑制與持續(xù) 24 小時(shí)的 GTL-16 腫瘤中 c-Met 磷酸化的完全抑制相關(guān)。在 >50mg/kg/天的濃度水平下,未觀察到腫瘤生長(zhǎng)抑制的進(jìn)一步改善。[1] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 10 mg/mL (22.21 mM) 10% DMSO+90% Saline : 1 mg/mL (2.22 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. 2eq.HCl : 45 mg/mL (100 mM) |
關(guān)鍵字 | Cluster of differentiation 246 | c-Met/HGFR | PF02341066 | Inhibitor | ROS Kinase | Anaplastic lymphoma kinase | inhibit | CD246 | Autophagy | PF 02341066 | ALK tyrosine kinase receptor | Crizotinib | Anaplastic lymphoma kinase (ALK) |
相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Valproic Acid | Taurine | Gefitinib | Aceglutamide | Hydroxychloroquine | Curcumin | Stavudine | Acetylcysteine | Paeonol | Sodium 4-phenylbutyrate |
相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | 抗癌活性化合物庫(kù) | 已知活性化合物庫(kù) | EMA 上市藥物庫(kù) | 激酶抑制劑庫(kù) | FDA 上市藥物庫(kù) | 酪氨酸激酶分子庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.2651萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營(yíng)模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP9年
|
滄州恩科醫(yī)藥科技有限公司
|
2024-12-28 | |
詢價(jià) |
VIP6年
|
武漢弘德悅欣醫(yī)藥科技有限公司
|
2024-12-28 | |
詢價(jià) |
VIP1年
|
湖北鴻福達(dá)生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP6年
|
武漢裕清嘉衡藥業(yè)有限公司
|
2024-12-27 | |
詢價(jià) |
VIP3年
|
深圳藥緣研發(fā)中心有限公司
|
2024-12-27 | |
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP1年
|
濟(jì)南洣林醫(yī)藥技術(shù)有限公司
|
2024-12-27 | |
¥100 |
VIP2年
|
蘇州海景醫(yī)藥科技有限公司
|
2024-12-27 | |
¥230.00 |
VIP8年
|
上海博景化工有限公司
|
2024-12-27 | |
詢價(jià) |
VIP7年
|
武漢貝爾卡藥業(yè)有限公司
|
2024-12-26 |